Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.0952W HIGH $16.34
Volume
70.28 K
Value Traded
379.62 K
Short % Float
8.32%
+9.66%Week
-28.65%1 Month
-9.39%3 Month
-65.29%6 Month
+84.56%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
143.52 M
EPS (TTM)
-5.17
P/E Ratio
-
Ent. Value
119.57 M
Total Shares
37.18 M
Float Shares
11.58 M
Insiders
68.86%
Institutions
13.39%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ARMP Catalyst Timeline
Dated clinical, regulatory and corporate events for Armata Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Armata Pharmaceuticals, Inc.
616Total events
3Upcoming
117Tier-1 (high impact)
2004 to 2043Coverage
Upcoming catalysts 2
Event history 50
▲Patent GrantedAP-SA02FiledIP / Competition
USPTO issued U.S. Patent No. 12,751,983 covering bacteriophage compositions for treating Staphylococcus infection with AP-SA02
Staphylococcus aureus infectionssource ↗
▲Grant / FundingAP-SA02FiledCorporate
Armata receives additional $3.7M non-dilutive DoW funding for AP-SA02 Phase 3
complicated Staphylococcus aureus bacteremiasource ↗
●Oral PresentationAP-SA02FiledPresentation
Oral presentation of AP-SA02 genomic diversity data at ISSSI 2026
Staphylococcus aureus bacteremiasource ↗
▲Additional DataAP-SA02FiledClinical Data
Genomic and functional data showing controlled genetic diversity in AP-SA02 may enhance killing of S. aureus clinical isolates
Staphylococcus aureus bacteremia (MSSA/MRSA)source ↗
▲Breakthrough Therapy DesignationAP-SA02FiledDesignation
FDA grants Breakthrough Therapy Designation to AP-SA02 for complicated S. aureus bacteremia
complicated Staphylococcus aureus bacteremia (MSSA or MRSA)source ↗
▲PublicationAP-PA02Presentation
Publication of paper on Ar-KM phage genome ejection in Journal of Molecular Biology
Pseudomonas aeruginosa infectionsource ↗
●FDA Filing AcceptedAP-SA02FiledRegulatory Filing
Submission of complete Phase 3 superiority protocol to FDA
complicated S. aureus bacteremiasource ↗
▲FDA Feedback ReceivedAP-SA02FiledFDA Meeting
FDA agreement on Agreed Initial Pediatric Study Plan (iPSP)
complicated S. aureus bacteremiasource ↗
▲Fast Track DesignationAP-SA02FiledDesignation
FDA granted Fast Track designation to AP-SA02
complicated bacteremia caused by MSSA or MRSAsource ↗
▲Pediatric Exclusivity GrantedAP-SA02FiledFDA Decision
FDA agreement on Agreed Initial Pediatric Study Plan (iPSP)
complicated S. aureus bacteremiasource ↗
▲Milestone PaymentAP-SA02FiledCorporate
Received $2.5 million additional non-dilutive funding from DoW
●PublicationAP-PA02Presentation
Publication of paper on Pakpunavirus P7-1 structure in Communications Biology
Pseudomonas aeruginosa infectionsource ↗
●End Of Phase 2 MeetingAP-SA02FiledFDA Meeting
End-of-Phase 2 meeting with FDA completed
complicated Staphylococcus aureus bacteremiasource ↗
▲FDA Filing AcceptedAP-SA02FiledRegulatory Filing
Complete Phase 3 superiority protocol submitted to FDA
complicated Staphylococcus aureus bacteremiasource ↗
▲FDA Feedback ReceivedAP-SA02FiledFDA Meeting
FDA agreement on Initial Pediatric Study Plan for AP-SA02
complicated Staphylococcus aureus bacteremiasource ↗
▲QIDPAP-SA02FiledDesignation
FDA granted QIDP designation for AP-SA02
complicated Staphylococcus aureus bacteremiasource ↗
▲Fast Track DesignationAP-SA02FiledDesignation
FDA granted Fast Track designation for AP-SA02
complicated Staphylococcus aureus bacteremiasource ↗
▲Debt Royalty FinancingCorporate
Entered into secured credit agreement with Innoviva for $25 million maturing in 2029
▲Fast Track DesignationAP-SA02FiledDesignation
FDA grants Fast Track Designation for AP-SA02
complicated bacteremia caused by methicillin-sensitive Staphylococcus aureus (MSSA) or methicillin-resistant Staphylococcus aureus (MRSA)source ↗
●PublicationAP-PA02Presentation
Structural biology publication on phage P7-1 in Communications Biology
chronic respiratory infections due to Pseudomonas aeruginosa in cystic fibrosis and non-cystic fibrosis bronchiectasissource ↗
▲Patent GrantedAP-PA02IP / Competition
USPTO issued U.S. Patent No. 12,594,312 covering bacteriophage compositions for treating Pseudomonas infection with AP-PA02
Pseudomonas infectionssource ↗
◆Trial InitiationAP-SA02FiledTrial
Phase 3 superiority study initiation planned for AP-SA02
complicated bacteremia caused by Staphylococcus aureussource ↗
▲End Of Phase 2 MeetingAP-SA02FiledFDA Meeting
End-of-Phase 2 meeting with FDA for AP-SA02
complicated S. aureus bacteremiasource ↗
▲QIDPAP-SA02FiledDesignation
FDA grants QIDP designation for AP-SA02 for adjunct treatment of complicated bacteremia caused by S. aureus
complicated bacteremia caused by Staphylococcus aureussource ↗
▲Debt Royalty FinancingCorporate
Amendments to credit agreements extending maturity to June 1, 2027
▲End Of Phase 2 MeetingAP-SA02FiledFDA Meeting
End-of-Phase 2 meeting with FDA concluded; FDA agreed Phase 2a data support advancement to Phase 3
complicated Staphylococcus aureus bacteremiasource ↗
▲QIDPAP-SA02FiledDesignation
QIDP request submitted to FDA
complicated Staphylococcus aureus bacteremiasource ↗
◆Oral PresentationAP-SA02FiledPresentation
KOL webinar on S. aureus bacteremia and AP-SA02 hosted by Jones Research
Staphylococcus aureus bacteremiasource ↗
▲Topline ReadoutAP-SA02FiledClinical Data
Compelling efficacy data from Phase 1b/2a study of AP-SA02
complicated Staphylococcus aureus bacteremiasource ↗
▲Manufacturing MilestoneCMC / Inspection
Full commissioning of cGMP manufacturing facility in Los Angeles
▲Manufacturing MilestoneCMC / Inspection
Formal commissioning of cGMP phage manufacturing facility in Los Angeles
▲Oral PresentationAP-SA02FiledPresentation
Late-breaking oral presentation of positive Phase 2a diSArm study results at IDWeek 2025
complicated Staphylococcus aureus bacteremiasource ↗
▲Primary Endpoint MetAP-SA02FiledClinical Data
Day 12 clinical response rates higher in AP-SA02 group vs placebo (88% vs 58%, p=0.047)
complicated Staphylococcus aureus bacteremiasource ↗
▲Oral PresentationAP-SA02FiledPresentation
Positive Phase 2a diSArm results highlighted in late-breaking oral presentation at IDWeek 2025
complicated Staphylococcus aureus bacteremiasource ↗
▲Topline ReadoutAP-SA02FiledClinical Data
Positive Phase 2a diSArm results highlighted in late-breaking oral presentation at IDWeek 2025
complicated Staphylococcus aureus bacteremiasource ↗
▲Late-BreakerAP-SA02FiledPresentation
Positive Phase 2a diSArm results highlighted in late-breaking oral presentation at IDWeek 2025
complicated Staphylococcus aureus bacteremiasource ↗
◆Oral PresentationPresentation
Armata corporate presentation at H.C. Wainwright 27th Annual Global Investment Conference
●PublicationAP-PA02Presentation
Publication of high-resolution Cryo-EM analysis of phage Pa223 in Journal of Molecular Biology
chronic respiratory infections in cystic fibrosis and non-cystic fibrosis bronchiectasissource ↗
Past FDA Catalysts and PDUFA Decisions
How ARMP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-03-31 | AP-SA02 | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D35 / 100
Pipeline Score
$7M
Pipeline Value
Richly Valued
Valuation Signal
5
Drugs Scored
0.1x
rNPV / MCap
Top 53%
Micro Cap(rank 349 of 658)
Percentile Rank
Armata Pharmaceuticals, Inc. faces pipeline headwinds (35/100), with $584M risk-adjusted pipeline value, led by C16G2 Varnish in Dental Caries (Phase 2), across $74B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| C16G2 Varnish Small moleculeCompletedNCT03004365 | Dental Caries | Phase 2 | COMPLETED | 33 | Mar 29, 2017 |
Clinical Trial Results
Readouts, endpoints and source filings for every ARMP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| AP-SA02 BreakthroughFast Track | complicated bacteremia caused by methicillin-sensitive S. aureus or methicillin-resistant S. aureus | Phase 2a | 2026-09-21 | 100% of AP-SA02-treated participants with an evaluable end-of-study assessment achieved a complete clinical responseRead More | Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical IsolatesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Birx DeborahDirector, Officer (Chief Executive Officer) | Disposition | -14,041 198,417 held | $4.26 | 07/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ARMP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ARMP for Q2 2026. | ||||
ARMP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ARMP ranks across every disease it competes in
Competitive Position is a premium feature
See how ARMP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialARMP News
ARMP▲ +1.3%today
Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
Armata Pharmaceuticals has announced the issuance of two new patents for its bacteriophage programs, AP-SA02 and AP-PA02, by the USPTO. These patents provide intellectual property protection until at least 2041, reinforcing Armata's position in the development of therapies for antibiotic-resistant infections. The company plans to advance AP-SA02 into a Phase 3 superiority study later this year.
Read more →ARMP▼ -13.3%on this newsshared move
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
Armata Pharmaceuticals has secured an additional $3.7 million in non-dilutive funding from the U.S. Department of War to advance its Phase 3 development of AP-SA02, a treatment for complicated Staphylococcus aureus bacteremia. This funding increases the total support for the program to $32.4 million, highlighting the government's ongoing commitment to addressing antibiotic-resistant infections. The company plans to initiate a Phase 3 superiority study in the latter half of 2026.
Read more →ARMPArmata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
Armata Pharmaceuticals presented data at the ISSSI 2026 showing that controlled genetic diversity in its AP-SA02 bacteriophage cocktail may enhance its effectiveness against certain Staphylococcus aureus isolates. The findings support the product's ability to adapt and kill diverse clinical strains, bolstered by positive results from a Phase 2a study. The company plans to initiate a Phase 3 study in the second half of 2026.
Read more →ARMPArmata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Armata Pharmaceuticals has received Breakthrough Therapy designation from the FDA for AP-SA02, an innovative treatment for complicated Staphylococcus aureus bacteremia. This designation is based on promising Phase 2 clinical trial data indicating significant improvements over existing therapies. AP-SA02 also holds Fast Track and QIDP designations, highlighting its potential in addressing serious bacterial infections.
Read more →ARMPArmata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Armata Pharmaceuticals will participate in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026. CEO Deborah Birx is set to present on September 16, highlighting the company's advancements in bacteriophage therapeutics aimed at treating antibiotic-resistant infections. This participation underscores Armata's commitment to innovative therapies.
Read more →ARMPArmata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
Armata Pharmaceuticals announced a new publication in the Journal of Molecular Biology detailing the structural biology of its bacteriophage Ar-KM, which targets Pseudomonas aeruginosa. The research provides insights into genome delivery and stability of the phage, crucial for developing effective therapies against antibiotic-resistant infections. This marks the fourth publication from their collaboration, indicating ongoing advancements in phage therapy.
Read more →ARMP▲ +11.8%on this news
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
Armata Pharmaceuticals reported its financial results for Q2 2026, highlighting progress in its clinical development of AP-SA02, a bacteriophage therapeutic for complicated S. aureus bacteremia. The company is set to initiate a pivotal Phase 3 study later this year, having received FDA Fast Track designation and additional funding. Despite operational losses, Armata's advancements in regulatory and manufacturing processes reflect a positive trajectory.
Read more →ARMP▲ +12.2%on this news
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
Armata Pharmaceuticals has made significant strides in advancing its AP-SA02 product candidate towards a Phase 3 superiority study. The company has submitted comprehensive responses to FDA feedback and completed engineering runs necessary for clinical trial material production. The Phase 3 study is scheduled to begin in the latter half of 2026, with additional funding from the Department of Defense supporting these efforts.
Read more →ARMP▼ -6.8%on this news
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
Armata Pharmaceuticals has received FDA agreement on an Initial Pediatric Study Plan for AP-SA02, aimed at treating complicated Staphylococcus aureus bacteremia in pediatric patients. This regulatory milestone supports the company's efforts to expand treatment options for vulnerable young patients. The plan outlines a pediatric development program following adult Phase 3 study results, emphasizing patient safety and efficient clinical development.
Read more →ARMPArmata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
Armata Pharmaceuticals has secured an additional $2.5 million in non-dilutive funding from the U.S. Department of Defense, bringing the total award to $28.7 million. This funding will support the Phase 3 readiness of their lead candidate, AP-SA02, aimed at treating complicated Staphylococcus aureus bacteremia. The company plans to initiate a Phase 3 study in the latter half of 2026.
Read more →ARMP▼ -7%on this news
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
Armata Pharmaceuticals reported its Q1 2026 financial results, highlighting progress in its lead therapeutic phage candidate AP-SA02, which is set to enter a Phase 3 study for complicated S. aureus bacteremia. The FDA has granted both QIDP and Fast Track Designation for this candidate. Despite these advancements, the company reported a significant net loss and a decrease in cash reserves.
Read more →ARMPArmata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
Armata Pharmaceuticals has received FDA Fast Track Designation for its product candidate AP-SA02, aimed at treating complicated bacteremia caused by Staphylococcus aureus. This designation allows for more frequent FDA interactions and a rolling review process, potentially expediting approval. The company plans to initiate a Phase 3 superiority study in late 2026, following positive results from earlier trials.
Read more →ARMP▲ +10.8%on this newsshared move
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
Armata Pharmaceuticals announced a publication in Communications Biology detailing the structure of phage P7-1, part of its AP-PA02 cocktail for treating Pseudomonas aeruginosa infections. The study highlights the phage's stability and infection mechanisms, contributing to the development of next-generation phage therapeutics. Armata's ongoing research aims to deepen the understanding of phage biology.
Read more →ARMP▼ -14.9%on this news
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors
Armata Pharmaceuticals has appointed Daniel B. Gilmer, Ph.D., to its Board of Directors, effective April 24, 2026. Dr. Gilmer, a seasoned executive with experience at Pfizer, will contribute his expertise in antimicrobial resistance and commercial strategy to advance Armata's bacteriophage therapeutics. His background includes leading the launch of PAXLOVID and involvement in various anti-infective initiatives.
Read more →ARMP▲ +8.6%on this news· ran to +19% by day 3
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
Armata Pharmaceuticals reported its financial results for Q4 and full-year 2025, showing a net loss of $124.3 million, primarily due to a significant impairment charge. The company recognized a decrease in grant revenue and research expenses, while general and administrative costs slightly increased. Despite these challenges, Armata continues to focus on developing bacteriophage therapeutics for antibiotic-resistant infections.
Read more →ARMPArmata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
Armata Pharmaceuticals announced a delay in reporting its fourth quarter and full-year 2025 financial results, which are now expected to be filed by March 31, 2026. Alongside this, the company highlighted positive developments regarding its AP-SA02 therapy, including successful results from a Phase 2a study and alignment with the FDA for future clinical trials. This positions Armata to initiate a Phase 3 superiority study later in the year, which could enhance treatment options for severe bacterial infections.
Read more →ARMP▲ +9.3%on this news· ran to +36% by day 1
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
Armata Pharmaceuticals has received FDA Qualified Infectious Disease Product (QIDP) designation for its multi-phage product candidate AP-SA02, aimed at treating complicated bacteremia caused by Staphylococcus aureus. This designation provides five years of market exclusivity and eligibility for fast track and priority review. The company plans to initiate a Phase 3 superiority study in late 2026.
Read more →ARMPArmata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia
Armata Pharmaceuticals has received FDA approval to advance its bacteriophage product candidate, AP-SA02, to a Phase 3 clinical study for treating complicated Staphylococcus aureus bacteremia. The FDA confirmed that data from the Phase 2a diSArm study supports this advancement. The Phase 3 study is expected to start in the second half of 2026, with a focus on demonstrating the superiority of AP-SA02 over existing treatments.
Read more →ARMPArmata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST
Armata Pharmaceuticals will host a key opinion leader webinar on November 25, 2025, focusing on S. aureus bacteremia and its phage therapy candidate, AP-SA02. The event will feature Dr. Vance G. Fowler from Duke University, who will discuss the complexities of S. aureus infections and the implications of Armata's research. This follows positive findings from the diSArm study presented at IDWeek 2025.
Read more →ARMPArmata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update
Armata Pharmaceuticals reported its third quarter 2025 results, highlighting promising efficacy data from its AP-SA02 study targeting Staphylococcus aureus infections. The company is preparing for late-stage clinical trials and has completed two Phase 2 trials. Financially, Armata's grant revenue has decreased, but it has improved operational efficiency and cash reserves.
Read more →About Armata Pharmaceuticals, Inc.
Headquarters5005 MCCONNELL AVE, LOS ANGELES, CA, 90066
Founded20-05-1994
BIOPHARMAWATCH ELITE PLUS
Trade the next ARMP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime